PROK earnings analysis
What we found in PROK's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing adds a material going-concern warning, stating that ProKidney’s existing cash resources of $181,564,000 will not support its anticipated operations for at least 12 months after the August 10, 2026 filing date. The company also reported an accumulated deficit of $1,318,294,000 and expects significant and increasing operating losses as research, development, and clinical activities continue. The extracted filing does not include the current-quarter income statement, balance sheet detail, cash flow statement, or segment disclosures, so revenue, margin, EPS, and free-cash-flow trends cannot be independently quantified from the provided text.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls Remained Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- New Going-Concern Warning
- The company reported an accumulated deficit of $1,318,294,000 as of June 30, 2026 and cash and cash equivalents plus marketable securities of $181,564,000. Based on its current business plan, existing cash resources will not fund anticipated operations for at least the 12 months following the August 10, 2026 filing date, creating substantial doubt about going-concern status.
What they said about what is next.
No numeric revenue or EPS guidance was provided in the extracted filing. Management states that cash resources will not fund the anticipated level of operations for at least the 12 months following the August 10, 2026 filing date.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- ProKidney Corp. reported a decline in revenue and an increase in net loss in the recent quarter, with total revenue at $0 and a net loss of $42.6 million. Operational expenditures rose due to increased R&D activities,…
- 10-K · March 18, 2026
- ProKidney positions itself as a late‑clinical‑stage biotech focused on a first‑in‑class autologous cell therapy, rilparencel, for advanced CKD with diabetes; rilparencel is stated to be “the only cell therapy in Phase 3…
- 10-Q · November 10, 2025
- ProKidney reported $217,000 of revenue in Q3 2025 and GAAP net loss per Class A share of $(0.12), an improvement vs. $(0.14) in Q3 2024. Operating loss narrowed to $(38,539) from $(48,973) in the prior-year quarter as…
- 10-Q · August 12, 2025
- ProKidney reported first meaningful product revenue of $221,000 in Q2 2025 and $451,000 year-to-date, while continuing to run substantial operating losses. Total operating expenses declined to $39.93 million in Q2 2025…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PROK makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever